There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report) and Warby Parker (WRBY – Research Report) with bullish sentiments.
Voyager Therapeutics (VYGR)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics today. The company’s shares closed last Wednesday at $8.97.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
Currently, the analyst consensus on Voyager Therapeutics is a Strong Buy with an average price target of $16.67.
See Insiders’ Hot Stocks on TipRanks >>
Warby Parker (WRBY)
In a report released today, Oliver Chen from TD Cowen maintained a Buy rating on Warby Parker, with a price target of $17.00. The company’s shares closed last Wednesday at $12.79.
According to TipRanks.com, Chen is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Warby Parker with a $17.80 average price target, implying a 33.3% upside from current levels. In a report issued on February 20, Robert W. Baird also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VYGR:
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
- Voyager Therapeutics reports selection of gene therapy development candidate
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
- VYGR Upcoming Earnings Report: What to Expect?
- Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
